Ключевые слова
Аннотация
Prostate cancer remains one of the most frequently diagnosed malignancies among men and continues to be a leading cause of cancer-related mortality worldwide [1]. Despite major advances in diagnostic technologies and therapeutic interventions, the disease presents substantial clinical challenges due to its pronounced biological heterogeneity and unpredictable progression patterns [2]. While some tumors exhibit indolent behavior and may never become clinically significant, others demonstrate aggressive growth and early metastatic potential, complicating treatment selection and prognostic assessment [4].
Библиографические ссылки
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023.
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019.
US Preventive Services Task Force. Screening for prostate cancer. JAMA. 2018.
Mottet N, et al. EAU Guidelines on Prostate Cancer. 2022.
Humphrey PA. Histopathology of prostate cancer. Cold Spring Harb Perspect Med. 2017.
Pritchard CC, et al. Inherited DNA-repair gene mutations in prostate cancer. N Engl J Med. 2016.
Yegnasubramanian S. Epigenetic alterations in prostate cancer. Nat Rev Urol. 2016.
Hanahan D, Weinberg RA. Hallmarks of cancer. Cell. 2011.
Feldman BJ, Feldman D. The androgen receptor in prostate cancer. Nat Rev Cancer. 2001.
Watson PA, Arora VK, Sawyers CL. Mechanisms of resistance in prostate cancer. Nat Rev Cancer. 2015.
Ahmed HU, et al. Diagnostic accuracy of mpMRI (PROMIS study). Lancet. 2017.
Epstein JI, et al. The Gleason grading system. Am J Surg Pathol. 2016.
Klotz L. Active surveillance for prostate cancer. Curr Urol Rep. 2015.
Mohler JL, et al. NCCN Guidelines: Prostate Cancer. 2023.
de Bono JS, et al. Advances in metastatic prostate cancer treatment. Lancet. 2020.